Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships.

Autor:	Molina-Montes E; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain. nmalats@cnio.es memolina@cnio.es., Van Hoogstraten L; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain., Gomez-Rubio P; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain., Löhr M; Gastrocentrum, Karolinska Institutet and University Hospital, Stockholm, Sweden., Sharp L; National Cancer Registry Ireland and HRB Clinical Research Facility, University College Cork, Cork, Ireland.; Newcastle University, Institute of Health & Society, Newcastle, United Kingdom., Molero X; Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Universitat Autònoma de Barcelona, CIBEREHD, Spain., Márquez M; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain., Michalski CW; Department of Surgery, Technical University of Munich, Munich, Germany.; Department of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Farré A; Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Perea J; Department of Surgery, Hospital 12 de Octubre, Madrid, Spain.; Department of Surgery and Health Research Institute, Fundación Jiménez Díaz, Madrid, Spain., O'Rorke M; Centre for Public Health, Belfast, Queen's University Belfast, United Kingdom.; College of Public Health, The University of Iowa, Iowa City, Iowa., Greenhalf W; Department of Molecular and Clinical Cancer Medicine, The Royal Liverpool University Hospital, Liverpool, United Kingdom., Ilzarbe L; Hospital del Mar-Parc de Salut Mar, Barcelona, CIBERONC, Spain., Tardon A; Department of Medicine, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, CIBERESP, Spain., Gress TM; Department of Gastroenterology, University Hospital of Giessen and Marburg, Marburg, Germany., Barberà VM; Molecular Genetics Laboratory, General University Hospital of Elche, Spain., Crnogorac-Jurcevic T; Barts Cancer Institute, Centre for Molecular Oncology, Queen Mary University of London, London, United Kingdom., Muñoz-Bellvis L; General and Digestive Surgery Department, Salamanca University Hospital, Spain., Domínguez-Muñoz E; Department of Gastroenterology, University Clinical Hospital of Santiago de Compostela, Spain., Balsells J; Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Universitat Autònoma de Barcelona, CIBEREHD, Spain., Costello E; Department of Molecular and Clinical Cancer Medicine, The Royal Liverpool University Hospital, Liverpool, United Kingdom., Iglesias M; Hospital del Mar-Parc de Salut Mar, Barcelona, CIBERONC, Spain., Kleeff J; Department of Surgery, Technical University of Munich, Munich, Germany.; Department of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Kong B; Department of Surgery, Technical University of Munich, Munich, Germany., Mora J; Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., O'Driscoll D; National Cancer Registry Ireland and HRB Clinical Research Facility, University College Cork, Cork, Ireland., Poves I; Hospital del Mar-Parc de Salut Mar, Barcelona, CIBERONC, Spain., Scarpa A; ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy., Yu J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stokholm, Sweden., Ye W; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stokholm, Sweden., Hidalgo M; Madrid-Norte-Sanchinarro Hospital, Madrid, Spain.; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Carrato A; Department of Oncology, Ramón y Cajal University Hospital, IRYCIS, Alcala University, Madrid and CIBERONC, Spain., Lawlor R; ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy., Real FX; Epithelial Carcinogenesis Group, Madrid, Spanish National Cancer Research Centre (CNIO), Madrid, Universitat Pompeu Fabra, Departament de Ciències Experimentals i de la Salut, Barcelona, and CIBERONC, Spain., Malats N
Jazyk:	angličtina
Zdroj:	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2020 May; Vol. 29 (5), pp. 1009-1018. Date of Electronic Publication: 2020 Feb 12.
DOI:	10.1158/1055-9965.EPI-19-1027
Abstrakt:	Background: Despite smoking being a well-established risk factor for pancreatic cancer, there is a need to further characterize pancreatic cancer risk according to lifespan smoking patterns and other smoking features, such as tobacco type. Our aim was to deeply investigate them within a large European case-control study. Methods: Tobacco smoking habits and other relevant information were obtained from 2,009 cases and 1,532 controls recruited in the PanGenEU study using standardized tools. Multivariate logistic regression analysis was performed to evaluate pancreatic cancer risk by smoking characteristics and interactions with other pancreatic cancer risk factors. Fractional polynomials and restricted cubic splines were used to test for nonlinearity of the dose-response relationships and to analyze their shape. Results: Relative to never-smokers, current smokers [OR = 1.72; 95% confidence interval (95% CI), 1.39-2.12], those inhaling into the throat (OR = 1.48; 95% CI, 1.11-1.99) or chest (OR = 1.33; 95% CI, 1.12-1.58), and those using nonfiltered cigarettes (OR = 1.69; 95% CI, 1.10-2.61), were all at an increased pancreatic cancer risk. Pancreatic cancer risk was highest in current black tobacco smokers (OR = 2.09; 95% CI, 1.31-3.41), followed by blond tobacco smokers (OR = 1.43; 95% CI, 1.01-2.04). Childhood exposure to tobacco smoke relative to parental smoking was also associated with increased pancreatic cancer risk (OR = 1.24; 95% CI, 1.03-1.49). Dose-response relationships for smoking duration, intensity, cumulative dose, and smoking cessation were nonlinear and showed different shapes by tobacco type. Effect modification by family history of pancreatic cancer and diabetes was likely. Conclusions: This study reveals differences in pancreatic cancer risk by tobacco type and other habit characteristics, as well as nonlinear risk associations. Impact: This characterization of smoking-related pancreatic cancer risk profiles may help in defining pancreatic cancer high-risk populations. (©2020 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu